Norditropin 45iu (15mg)

Norditropin 45 IU (15mg/1.5mL) is a prescription somatropin product supplied as a ready-to-use solution for injection in a cartridge. Each 1.5 mL cartridge contains 15 mg of somatropin, equivalent to 45 International Units (IU), with a concentration of 10 mg/mL. Somatropin is recombinant human growth hormone produced using recombinant DNA technology. The solution should be clear and colourless before use.

Norditropin 45 IU (15mg/1.5mL) Product Details

Brand: Norditropin SimpleXx
Active ingredient: Somatropin
Strength: 15 mg/1.5 mL
Equivalent strength: 45 IU per cartridge
Concentration: 10 mg/mL
Dosage form: Solution for injection
Presentation: Multi-dose glass cartridge
Manufacturer / Marketing Authorisation Holder: Novo Nordisk A/S, Denmark
Device compatibility: Matching NordiPen 15 system
Prescription status: Prescription medicine

Cartridge Presentation

Norditropin 45 IU (15mg/1.5mL) is supplied as a prepared cartridge rather than a powder that requires reconstitution before use. The cartridge contains a ready-made somatropin solution, removing the additional mixing step required with some other growth hormone preparations.

The 15 mg strength uses green colour coding and is intended for the matching NordiPen 15 device. Using the correct compatible injection device is important because the pen system is designed for the cartridge strength and concentration.

Medical Use

Norditropin is used as growth hormone replacement therapy for specific medically diagnosed conditions. Depending on the patient and applicable prescribing information, recognised uses may include growth failure caused by growth hormone deficiency in children, Turner syndrome, certain growth problems associated with chronic renal disease, short stature in children born small for gestational age who have not achieved appropriate catch-up growth, and growth failure associated with Noonan syndrome. It may also be prescribed for adults with confirmed growth hormone deficiency.

Treatment should be based on a confirmed medical indication rather than age, height, body weight, appearance, or athletic goals. A qualified healthcare professional should determine the appropriate dose using clinical assessment, laboratory monitoring, treatment response, and individual risk factors.

Cartridge and Solution

The Norditropin 45 IU (15mg/1.5mL) cartridge contains the solution in a Type I glass container. The formulation should remain clear and colourless. Do not use the cartridge if the solution appears cloudy, discoloured, or otherwise abnormal.

Norditropin SimpleXx should not be shaken vigorously. The cartridge and injection device should be handled according to the instructions supplied with the medicine. Only the compatible device intended for the specific cartridge strength should be used.

Storage and Handling

Unopened Norditropin 45 IU (15mg/1.5mL) should be stored in a refrigerator at 2°C to 8°C and kept inside its outer carton to protect it from light. Do not freeze the cartridge or place it directly beside a cooling element.

After first opening, product information permits storage for up to four weeks under refrigeration at 2°C to 8°C. Alternatively, it may be stored for up to three weeks below 25°C. Storage instructions supplied with the individual pack should always be followed because authorised presentations and requirements can vary by country.

Important Safety Information

Somatropin requires medical supervision. It should not be used in patients with active tumours and may be unsuitable during certain acute critical illnesses. Growth hormone treatment can affect glucose metabolism, and monitoring of blood glucose, thyroid function, IGF-1 levels, treatment response, and other clinical factors may be required.

Persistent severe headache, visual disturbances, nausea, vomiting, unusual swelling, significant joint or muscle symptoms, or other unexpected reactions should be discussed promptly with a healthcare professional.

Injection devices and needles should not be shared between patients. The prescribed dose is individual and should not be increased, reduced, or otherwise changed without appropriate medical guidance.

Supply Information

Norditropin is a prescription medicine. Packaging, batch details, expiry date, refrigeration history, and cartridge integrity should be checked before supply or use.

Availability, approved indications, pack configuration, injection devices, and prescription requirements may differ between countries. Norditropin 45 IU (15mg/1.5mL) should be supplied only where legally permitted and in accordance with applicable prescription and pharmacy requirements.